XML 67 R35.htm IDEA: XBRL DOCUMENT v3.20.4
Discontinued Operations (Tables)
 12 Months Ended
Dec. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]  
Disposal Groups, Including Discontinued Operations
The carrying values of the major classes of assets and liabilities included in assets and liabilities held for abandonment for MBP Titan as of December 31, 2020 and 2019, are as follows:
December 31,
20202019
Assets
Property, plant and equipment, net$586 $17,017 
Goodwill— 9,635 
Right-of-use assets9,131 13,425 
Other assets136 636 
Total assets held for sale or abandonment$9,853 $40,713 
Liabilities
Lease liabilities, current$1,890 $1,548 
Other current liabilities619 1,657 
Lease liabilities, net of current portion11,538 13,730 
Total liabilities held for sale or abandonment$14,047 $16,935 
The following table presents the financial results of discontinued operations of MBP Titan:
Year Ended December 31,
202020192018
Operating expenses (1)$40,692 $37,423 $33,830 
Operating loss(40,692)(37,423)(33,830)
Loss before income taxes(40,692)(37,423)(33,830)
Loss from discontinued operations$(40,692)$(37,423)$(33,830)
(1)Includes a goodwill impairment charge of $9,635 and an impairment charge on property, plant and equipment and ROU Assets of $12,406 recorded in 2020 in conjunction with the suspension of MBP Titan's operations discussed above.
The following table presents the significant non-cash items and purchases of property, plant and equipment for the discontinued operations for MBP Titan that are included in the accompanying consolidated statements of cash flows.
Year Ended December 31,
202020192018
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization$2,474 $3,647 $3,493 
Impairment of goodwill9,635 — — 
Impairment of other noncurrent assets12,406 — — 
Stock-based compensation expense(34)1,345 1,870 
Cash flows from investing activities
Purchases of property, plant and equipment(88)(2,114)(3,558)
The carrying values of the major classes of assets and liabilities included in assets and liabilities held for sale for the Transactions as of December 31, 2019 are as follows:
 TS Biotechnology SaleEnviroFlight SaleTotal
Assets
Cash and cash equivalents$2,223 $— $2,223 
Other current assets9,698 — 9,698 
Property, plant and equipment, net51,975 — 51,975 
Intangible assets, net20,891 4,383 25,274 
Investments in affiliates— 7,817 7,817 
Right-of-use assets13,622 — 13,622 
Other noncurrent assets212 — 212 
Total assets held for sale$98,621 $12,200 $110,821 
Liabilities
Deferred revenue, current (1)$8,723 $— $8,723 
Lease liabilities, current2,459 — 2,459 
Other current liabilities3,058 41 3,099 
Deferred revenue, net of current portion (2)19,410 — 19,410 
Lease liabilities, net of current portion12,623 — 12,623 
Other long-term liabilities1,019 — 1,019 
Total liabilities held for sale$47,292 $41 $47,333 
(1)Includes deferred revenue, current, from related parties of $1,243.
(2)Includes deferred revenue, net of current portion, from related parties of $6,836.
The following tables present the financial results of discontinued operations related to the Transactions:
 Year Ended December 31, 2020
 TS Biotechnology SaleEnviroFlight SaleTotal
Revenues (1)$1,294 $— $1,294 
Operating expenses896 — 896 
Operating income398 — 398 
Gain on sale of discontinued operations633 39 672 
Loss on release of cumulative foreign currency translation adjustment(26,957)— (26,957)
Other expense, net(129)— (129)
Equity in net loss of affiliates— (38)(38)
Income (loss) before income taxes(26,055)1 (26,054)
Income tax expense(2)— (2)
Income (loss) from discontinued operations$(26,057)$1 $(26,056)
(1)Includes revenues recognized from related parties of $436.
 Year Ended December 31, 2019
 TS Biotechnology SaleEnviroFlight SaleTotal
Revenues (1)$12,307 $— $12,307 
Operating expenses (2)116,091 10,794 126,885 
Operating loss(103,784)(10,794)(114,578)
Other expense, net(272)— (272)
Equity in net loss of affiliates— (4,314)(4,314)
Loss before income taxes(104,056)(15,108)(119,164)
Income tax benefit3,005 — 3,005 
Loss from discontinued operations$(101,051)$(15,108)$(116,159)
(1)Includes revenue recognized from related parties of $3,042.
(2)Includes the impairment charge of $89,679 related to the Transactions discussed above.
 Year Ended December 31, 2018
 TS Biotechnology SaleEnviroFlight SaleTotal
Revenues (1)$9,396 $— $9,396 
Operating expenses (2)111,039 470 111,509 
Operating loss(101,643)(470)(102,113)
Other expense, net(1,757)— (1,757)
Equity in net loss of affiliates— (2,622)(2,622)
Loss before income taxes(103,400)(3,092)(106,492)
Income tax benefit6,103 — 6,103 
Loss from discontinued operations$(97,297)$(3,092)$(100,389)
(1)Includes revenue recognized from related parties of $4,665.
(2)Includes an impairment charge of $60,504 recorded in 2018 related to Oxitec's developed technology targeting the Aedes Aegypti mosquito and a $5,057 loss on disposal of certain leasehold improvements, equipment and other fixed assets in conjunction with the closing of one of Oxitec's research and development facilities in Brazil.
The following table presents the significant non-cash items, investments in EnviroFlight and purchases of property, plant and equipment for the discontinued operations for the Transactions that are included in the accompanying consolidated statements of cash flows.
Year Ended December 31,
202020192018
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization$— $5,107 $9,007 
Impairment of goodwill— 58,042 — 
Impairment of other noncurrent assets— 31,637 60,504 
Gain on sale of discontinued operations(672)— — 
Loss on release of cumulative foreign currency translation adjustment26,957 — — 
Unrealized and realized depreciation on equity securities and preferred stock, net106 458 1,927 
Equity in net loss of EnviroFlight38 4,314 2,622 
Stock-based compensation expense(1,346)2,507 3,872 
Deferred income taxes— (2,710)(5,703)
Cash flows from investing activities
Investments in EnviroFlight— (2,000)(12,250)
Purchases of property, plant and equipment(382)(23,326)(21,191)
Summarized financial data for equity method investments included in discontinued operations during the periods below are shown in the following tables.
December 31,
 2019
Current assets$703 
Noncurrent assets30,549 
Total assets31,252 
Current liabilities2,352 
Non-current liabilities88 
Total liabilities2,440 
Net assets$28,812 
 Year Ended December 31,
 202020192018
Revenues$16 $510 $268 
Operating expenses92 9,159 12,709 
Operating loss(76)(8,649)(12,441)
Other, net— 21 39 
Net loss$(76)$(8,628)$(12,402)